Compare Johnson & Johnson (JNJ) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Johnson & Johnson trades at $248.49 (market cap $598.96B), while Direxion Daily FTSE China Bull 3x Shares trades at $28.55. The key difference: Johnson & Johnson pays a 2.15% dividend while Direxion Daily FTSE China Bull 3x Shares pays none, and Johnson & Johnson is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| JNJ | YINN | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $267.24 | $56.62 |
52-Week Low | $164.36 | $21.45 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
YINN (Direxion Daily FTSE China Bull 3x ETF) trades at $28.89, up 7.84% with a bullish technical signal. The leveraged ETF structure amplifies exposure to Chinese equities, which face mixed sentiment amid economic stabilization efforts and US-China tensions. Moving averages show bullish momentum while oscillators remain neutral, with key resistance at $27.
Outlook remains volatile given YINN's 3x leverage structure and China's economic crosscurrents. Investment opportunity exists for tactical traders betting on China's infrastructure and AI stimulus, but risks include geopolitical friction and leveraged decay. The fund's performance hinges on Beijing's policy effectiveness versus US restrictions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
